Check for updates

OPEN ACCESS

EDITED BY Chunping Wan, First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine, China

REVIEWED BY Eva Pastille, Essen University Hospital, Germany Vijay Morampudi, University of Hyderabad, India

*CORRESPONDENCE Chuanxiang Zhao Zhao_cx@jscn.edu.cn

[†]These authors have contributed equally to this work and share first authorship

RECEIVED 07 October 2024 ACCEPTED 12 December 2024 PUBLISHED 07 January 2025

CITATION

Zhao C and Lin S (2025) PANoptosis in intestinal epithelium: its significance in inflammatory bowel disease and a potential novel therapeutic target for natural products. *Front. Immunol.* 15:1507065. doi: 10.3389/fimmu.2024.1507065

COPYRIGHT

© 2025 Zhao and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PANoptosis in intestinal epithelium: its significance in inflammatory bowel disease and a potential novel therapeutic target for natural products

Chuanxiang Zhao*† and Shan Lin†

Institute of Medical Genetics and Reproductive Immunity, School of Medical Science and Laboratory Medicine, Jiangsu College of Nursing, Huai'an, China

The intestinal epithelium, beyond its role in absorption and digestion, serves as a critical protective mechanical barrier that delineates the luminal contents and the gut microbiota from the lamina propria within resident mucosal immune cells to maintain intestinal homeostasis. The barrier is manifested as a contiguous monolayer of specialized intestinal epithelial cells (IEC), interconnected through tight junctions (TJs). The integrity of this epithelial barrier is of paramount. Consequently, excessive IEC death advances intestinal permeability and as a consequence thereof the translocation of bacteria into the lamina propria, subsequently triggering an inflammatory response, which underpins the clinical disease trajectory of inflammatory bowel disease (IBD). A burgeoning body of evidence illustrates a landscape where IEC undergoes several the model of programmed cell death (PCD) in the pathophysiology and pathogenesis of IBD. Apoptosis, necroptosis, and pyroptosis represent the principal modalities of PCD with intricate specific pathways and molecules. Ample evidence has revealed substantial mechanistic convergence and intricate crosstalk among these three aforementioned forms of cell death, expanding the conceptualization of PANoptosis orchestrated by the PNAoptosome complex. This review provides a concise overview of the molecular mechanisms of apoptosis, necroptosis, and pyroptosis. Furthermore, based on the crosstalk between three cell deaths in IEC, this review details the current knowledge regarding PANoptosis in IEC and its regulation by natural products. Our objective is to broaden the comprehension of innovative molecular mechanisms underlying the pathogenesis of IBD and to furnish a foundation for developing more natural drugs in the treatment of IBD, benefiting both clinical practitioners and research workers.

KEYWORDS

inflammatory bowel disease, intestinal epithelium, cell death, PANoptosis, natural products

1 Introduction

Inflammatory bowel disease (IBD) is a chronic idiopathic inflammation disease of the gastrointestinal tract, encompassing ulcerative colitis (UC) and Crohn's disease (CD) (1). Characterized by inflammation and recurrent ulceration, UC dominates the colonic mucosa, whereas CD manifests any parts of the entire gastrointestinal tract (2). A global epidemiological survey has demonstrated the rise prevalence not only in Western nations but also in emerging countries (3). Despite the ongoing ambiguity surrounding its etiology and pathogenesis, recent studies have elucidated that the intricate interplay between genetic, environmental and immune factors are indispensable trigger for progression to intestinal epithelial barrier damage (4). Consequently, the concept of "mucosal healing" that necessitate the complete regeneration of the intestinal mucosa has been raised as the therapeutic benchmark of IBD (5, 6). Mounting evidence underscores that mismanaged intestinal epithelial cells (IEC) death compromised barrier breach, which underlies instances of widespread epithelial erosion (7, 8). So undoubtedly, a more profound grasp of the IEC cell death paradigm is imperative.

Apoptosis, necroptosis, and pyroptosis are extensively studied forms of cellular demise, each featuring unique morphological and biochemical changes. These processes are meticulously choreographed by tightly-structured signaling cascades of reactions and molecules in response to a certain signal or stimuli, aiming at eliminating unwanted or damaged cells to maintain tissue homeostasis (9). Apoptosis is a non-lytic cell death with an integral cellular membrane and is considered immunologically silent. In contrast, necroptosis and pyroptosis are lytic and inflammatory form of unregulated and accidental cell death (9). Historically, it has been viewed that apoptosis, necroptosis, and pyroptosis act in parallel without overlap, but the three PCDs have recently shown to be tightly interconnected and interact with each other, laying a theoretical foundation for a novel form of PCD known as PANoptosis (10, 11). Comprehensive research has demonstrated abnormal apoptosis, necroptosis, and pyroptosis of IEC during the onset and progression of IBD as well as the complex crosstalk among them (7). Therefore, PANoptosis may represent an innovative therapeutic target for the effective treatment of IBD.

In this review, we present a concise summary of apoptosis, necroptosis, and pyroptosis, subsequently introducing a more elaborate understanding about the intricate interplay among them within IEC to investigate their potential relationship with IBD. Building on this foundation, we further detail the recent advance of PANoptosis in IEC and its regulation by natural products. We aims to offer theoretical basis and reference for targeting PANoptosis in IEC, thereby fostering the development of more effective therapeutic regimens and pharmacological interventions to improve the efficacy of IBD therapy in clinical practice.

2 The overview of apoptosis, necroptosis, and pyroptosis

2.1 Apoptosis

Apoptosis, the first discovered form of programmed cell death, is a physiological and proactive "conscious suicide" behavior (12). Under specific physiological or pathological conditions, apoptosis is initiated through either receptor-mediated (extrinsic) or mitochondria (intrinsic) pathways, marked initially by the cellular shrinkage and rounding, nuclear fragmentation and chromatin condensation (12). Subsequently, the apoptotic cell features the plasma membrane blistering, tightly encapsulating the cellular debris, culminating in forming the apoptotic bodies. Apoptotic bodies are engulfed by adjacent parenchymal cells and macrophages, and thus this process does not elicit an inflammation response in surrounding tissues (9, 12).

The extrinsic apoptotic pathway is initiated by the binding of extracellular death ligands (TNF family members or Fas ligand) to their corresponding death receptors (DR) on the plasma membrane. Following, the cytoplasmic death domain of death receptors recruits adapter proteins (FADD or TRADD), and then the precursor of caspase-8 is recruited to form the death-inducing signaling complex (DISC), activating the initiator caspase-8 and further activating effector caspases-3/7, ultimately leading to apoptosis (9). The intrinsic (mitochondria) apoptotic pathway is induced by internal apoptotic stimuli, such as oxidative stress, hypoxia, toxic substances, or cytokine deprivation. These stimuli cause the B-cell lymphoma-2 (Bcl-2) protein family to alter the permeability of the mitochondrial membrane, releasing cytochrome c within the mitochondria into the cytoplasm. Subsequently, cytochrome c binds to apoptotic protease activating factor-1 (Apaf-1), facilitating apoptosome assembly, which ignites pro-caspase-9 (13, 14). Then, the activated initiator caspase-9 further activates the effector proteins caspase-3/7, amplifying downstream signals and culminating in apoptosis (14).

2.2 Necroptosis

Necroptosis is a lytic and inflammatory form of PCD independent of caspases, typically occurring when pathogens or chemical mediators inhibit apoptosis (15). Morphologically, necroptotic cells feature with necrotic cells, including swollen mitochondria, the explosive rupture of plasma membrane and cell lysis with the leakage of cytosolic constituent into the surrounding tissues (9, 15).

Caspase-8 determines whether the cell undergoes apoptosis or necroptosis. When caspase-8 is inactivated or inhibited by pathogens or chemical mediators, the activated RIPK3-mediated necrosome is formed (16). Primarily, the external stimulus (such as TNF- α , Fas ligand and TLR ligands) binds to death receptors (such as TNFR1 and Fas) and pattern recognition receptors (PRRs, such as Toll-like receptor), which then recruits and activates receptorinteracting kinase 1 (RIPK1). Following, the activated RIPK1 recruits and phosphorylates receptor-interacting kinase 3 (RIPK3) to form the RIPK1-RIPK3 complex (necrosome), then recruiting and phosphorylating mixed lineage kinase domain-like (MLKL) (9). The phosphorylated MLKL translocates to cellular membranes and lyses the cell by forming membrane pores (17). The consequent membrane rupture results in the release of DAMPs, inevitably triggering an inflammation response.

2.3 Pyroptosis

Pyroptosis is a lytic and inflammatory form of PCD dependent of a series of caspase families to induce the assembly and activation of inflammasome in response to bacterial or pathogen infections (18). Pyroptotic cells exhibit the distinct and characterized morphology with cell swelling, DNA fragmentation within the intact nucleus and plasma membrane rupture, ultimately leading to cell lysis with the release of inflammatory factors (9).

Pyroptosis is induced by two primary mechanisms: the canonical (caspase-1 dependent inflammasome activation) and the non-canonical (caspase-1 independent inflammasome activation) pathways. In the canonical pathway, pattern recognition receptors (PRR), such as TLRs and Nod-like receptors (NLRs), sense pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) to initiate inflammasome sensors (19). The sensors generally comprise Nodlike receptor protein 3 (NLRP3), NLR family pyrin domaincontaining 1 (NLRP1), NLR family CARD domain containing 4 (NLRC4), absent in melanoma 2 (AIM2), and pyrin proteins, with NLRP3 being the most extensively studied. The activated inflammasome sensor then enlists the adapter protein apoptosisrelated speck-like protein (ASC) and pro-caspase-1 to form inflammasome (9). Then, pro-caspase-1 is hydrolyzed and converted into the catalytically active form caspase-1, which further cleaves gasdermin D (GSDMD), pro-IL-1 β and pro-IL-18. The processed GSDMD releases the N-terminal fragment of GSDMD (GSDMD-N), which inserts into the cell membrane to form pores to leaking the mature IL-1 β and IL-18 as well as other DAMPs, thereby amplify the inflammatory response (20).

The non-canonical pathway is launched by lipopolysaccharide (LPS) from gram-negative bacterial. LPS directly interacts with and activates human caspase-4/5 and its murine ortholog caspase-11 to cleave GSDMD, thus inducing inflammation (21, 22). Beyond forming membrane pores, GSDMD-N also facilitates the activation of the non-canonical NLRP3 inflammasome and caspase-1, which cleaves pro-IL-1 β and pro-IL-18 in a cellintrinsic manner (23). With in-depth investigates, the caspase-3/ 8-dependent pyroptotic pathway and the granzyme-mediated GSDMD- independent pyroptosis pathway have recently been revealed (24). When cell is treated with partial chemical inducers, pyroptosis is induced by caspase-3-mediated cleavage of GSDME, yielding a GSDME-N fragment with the pore-forming activity, while caspase-8 specifically cleaves GSDMC to trigger cell death pathway (24, 25). In addition, granzyme A/B involves in extensive pyroptosis by cleaving GSDMB and GSDME, respectively (26, 27).

3 The crosstalk among apoptosis, necroptosis, and pyroptosis in IEC involving in IBD

The appropriate model of IEC death is crucial for maintaining intestine homeostasis. However, excessive and abnormal IEC death programmers can have catastrophic consequences, such as the onset of inflammatory bowel diseases. The epithelium of patients with UC or CD manifests high level of cell deaths (7, 8). Substantial evidence have well-established the involvement of apoptosis, necroptosis, and pyroptosis of IEC in the onset of IBD. Simultaneously, the three models of cell death described above are interconnected and superimposed at multiple levels, which have been mostly described as 'crosstalk'. Caspase-8 and its adapter FADD are the core molecular bridging apoptosis, necroptosis and pyroptosis in IEC (7). In response to TNF and TLR, caspase-8 is activated, which not only ignites the downstream executioner caspase-3/7 in the apoptotic pathway, but also cleaves RIPK1 and RIPK3 in the necroptotic pathway (28–31). Additionally, caspase-8 and FADD process caspase-1, inflammasome assembly, and GSDMD activation to launch pyroptosis (31–33).

Caspase-8 switches apoptosis and necroptosis (Figure 1A). An early study demonstrated that TLR stimulation induced apoptosis and increased shedding of IEC under inflammatory conditions, which was related to the activated caspase-8 (34). The activated caspase-8 also processed gasdermin-D-mediated pyroptosis-like death of epithelial cells and ensuing ileitis (31). In situation where caspase-1 was deleted in IEC, the inflammasome sensors NLRP1b and NLRC4 triggered apoptosis by ASC-dependent caspase 8 activation (35). Under steady state conditions, caspase-8 curbs RIPK1 and RIPK3 activity by proteolytic cleavage in IEC, thereby impeding necroptosis (31). Thus, IEC lacking caspase-8 or FADD due to epithelial cell-specific deletion underwent RIPK3-dependent necroptosis instead of apoptosis in response to TLR or TNF stimulation, leading to a complete absence of Paneth cell, serious tissue damage, enteritis and severe erosive colitis in vivo (36-38). Similarly, the deficiency of intestinal epithelial caspase-8 signaling induced necroptosis-mediated enteritis and high lethality after Salmonella Typhimurium infection (39). Regarding RIPK1, mice suffering from the deficiencies in both RIPK1 and FADD in IECs displayed RIPK3-dependent IEC necroptosis, Paneth cell loss and focal erosive inflammatory lesions in the colon (40). In line with the results observed in mice, patients with a biallelic 710A > G mutation in the caspase-8 gene presented the increased necroptosis instead of apoptosis in the gut with non-resolving inflammation (41). The imaging in vivo showed that IEC necroptosis is considered the basis for the micro erosions and epithelial gaps observed in mice and humans, which is consistent with the significantly high expression of RIPK3 in the terminal ileum of CD patients (38, 42). Indeed, the specific cell type of IEC necroptosis may be Paneth cell. Paneth cells in humans and mice represented a high level of RIPK3 expression (38). Interestingly, Paneth cells without caspase-8 do develop but undergo necroptosis in vivo (38). As is well-known, Paneth cells are predominantly rich in the ileum. This may provide an explanation for why mice deficient in caspase-8 bear ileitis but no colitis (38). So far, however, no study has illustrated RIPK3 as a susceptibility gene for IBD in genetic research. This evidence hints that necroptosis of Paneth cells is not a causative factor, but rather a contributing factor supporting intestinal inflammation. In a word, necroptosis is frequently encountered in Paneth cells when apoptosis fails to be induced due to caspase-8 deficiency in IEC.

Although blocking apoptosis through restricting caspase-8 in IEC and switching their death to necroptosis cause overt intestinal



The mechanism of apoptosis, necroptosis and pyroptosis as well as the crosstalk among them in IEC. (A) The crosstalk between apoptosis and necroptosis as well as necroptosis and pyroptosis in IEC. Beyond cleaving the effector caspases-3/7 in the apoptotic pathway, the apoptotic molecule caspase-8 could cleave RIPK1, thus inhibiting necroptosis. In addition, the phosphorylated MLKL could foster ASC polymerization and following lead to caspase-1 activation to trigger pyroptosis. (B) The crosstalk between apoptosis and pyroptosis in IEC. The apoptotic molecule caspase-8 could process GSDMD activation and interact with ASC to launch pyroptosis. The apoptotic effector caspase-3 is indispensable for GSDME-mediated pyroptosis. When GSDMD is absent, the pyroptotic molecule caspase-1 proceeds to activate caspase-3/7 and caspase-9. The pyroptotic molecule GSDME-N fragment permeabilizes the mitochondrial membrane to induce cytochrome c release and ensuing activate the apoptotic molecule gapotose.

inflammation, it may be a self-protection mechanism evolved by the body when the caspase-8-dependent apoptotic pathway has been hijacked by microbes or viral infection. CrmA from the cowpox virus or B13R from the vaccinia virus encodes caspase-8 inhibitor, thus preventing infected cells from apoptosis; however, RIPK3dependent necroptosis serves as a backup mechanism for killing infected cells and ensures host survival (43, 44). Nevertheless, some pathogens prevent epithelial cell death by delivering effectors via the type III secretion system to inhibit both apoptosis and necroptosis, which can maintain their replicative niche and multiply within cells. For example, *Shigella flexneri* hijacked colonic epithelium via a dual mechanism: it yielded OspC1 to impede caspase-8, thus blocking apoptosis; simultaneously, it also yielded OspD3 to degrade RIPK1 and RIPK3, thereby preventing necroptosis (45).

Collectively, the afore-mentioned studies hint that co-inhibition of caspase-8 and RIPK3 seemingly protects IEC from cell death. Bewilderingly, mice with deletion of RIPK3 with the FLIP proteinsinduced caspase-8 inhibition in IEC protected from neither cell death nor inflammation (46). However, the co-ablation of caspase-8 and MLKL downstream of RIPK3 or FADD and RIPK3 in IEC fully protected against cell death and prevented ileitis in mice (31). These evidence imply the involvement of additional molecules in inducing cell apoptosis or necroptosis beyond caspase-8 or RIPK3, respectively. Alternatively, the involvement of another form of cell death in this process might provide another explanation for this observation.

Although no knowledge about additional molecules to induce cell necroptosis independent of RIPK3 has been established, some evidence point out the regulation of pyroptotic molecules on apoptosis beyond caspase-8 (Figure 1B). For instances, the canonical molecule of pyroptosis, caspase-1, could cleave the conventional aspartate activation sites (Asp²³ and Asp¹⁹⁸) of caspase-7 in macrophages in response to Salmonella Typhimurium infection combined with LPS and ATP (47). When GSDMD is absent, caspase-1 also proceeds to activate caspase-3 and caspase-9 as well as trigger mitochondrial damage in macrophages, thereby triggering the apoptotic signaling (48). In addition, GSDMD-N and GSDME-N fragments permeabilized the mitochondrial membrane to induce cytochrome c release and ensuing activate the apoptosome in HEK293T cells, fueling the mitochondrial apoptotic pathway (49). Further studies are required to address whether the regulation of pyroptotic molecules on apoptosis also exists in IEC and whether they affect IBD pathogenesis.

As for the involvement of another cell death, mounting evidence now point out significant contributions of pyroptosis in IECs to the onset of IBD, which could be regulated by apoptotic or necroptotic molecules (Figure 1). Elevated levels of GSDMB, GSDMD and GSDME were obviously detected in the inflamed colonic mucosa of IBD patients, predominantly localizing to the intestinal mucosal epithelium (50-52). The apoptotic effector caspase-3 is indispensable for TNBS-induced and GSDMEmediated pyroptosis in IEC (52). Studies with mice carrying enzymatically inactive caspase-8 revealed that the CASP8-RIPK1 platform shared by apoptosis and necroptosis was genetically associated with ASC, the adaptor protein of inflammasomes. The DED domain of caspase-8 in cells from these mice interacted with ASC, triggering pyroptosis and severe inflammation in the intestine (53, 54). Additionally, knockdown of caspase-8 or inhibition of its function promoted RIPK3-mediated inflammasome NLRP3 activation in macrophage, independent of MLKL (55). Similarly, MLKL could foster ASC polymerization and following lead to caspase-1 activation in response to combined treatment of a TLR3 agonist poly(I:C) and zVAD in macrophage (56). The effector molecule of necroptosis MLKL activated NLRP3 inflammasome (57, 58). Therefore, the IEC death in mice with co-ablating RIPK3 and caspase-8 could be rescued when the pyroptotic mediator was deleted (53, 54).

In summary, the crosstalk of events underlying apoptosis, necroptosis and pyroptosis in IEC can be succinctly outlined as follows: caspase-8 switches apoptosis and necroptosis in IEC (Figure 1). TLR or TNF immoderate stimulation induced the activation of caspase-8 in IEC, thus initiating an apoptotic fate. Concurrently, caspase-8 fosters gasdermin-D-mediated pyroptosislike death of epithelial cells. When caspase-8 is deleted or dysfunctional due to pathogen-mediated or pharmacological inhibition, caspase-8 mediated-apoptosis and pyroptosis could not be triggered, resulting in RIPK3-mediated necroptosis of IEC or additional molecules igniting apoptotic/pyroptosis signals in IEC. For example, caspase-1, GSDMD and GSDME induced apoptosis, while caspase-3 or MLKL orchestrate pyroptosis. These excessive cell death modalities, based on the crosstalk of molecules, collectively cause catastrophic intestinal inflammation.

4 The role of PANoptosis in IEC and its regulation by nature products

4.1 The role of PANoptosis in IEC

Based on the extensive cross-talk between PCD pathways, the conceptualization of a united cell death modality, named PANoptosis, was proposed in 2019 (59). PANoptosis ("P", pyroptosis; "A", apoptosis; "N", necroptosis) is induced by multifaceted PANoptosome complexes with key features of pyroptosis, apoptosis, and/or necroptosis, which could not be fully accounted for by any other PCD pathway alone. The PANoptosome components are tripartite, consisting of: 1) PAMPs or DAMPs sensors like ZBP1, AIM2, and NLRP3; 2) scaffolding proteins such as ASC and FADD; 3) catalytic effectors including RIPK1, RIPK3, CASP-1 and CASP-8 (59). To date, several distinct PANoptosome complexes have been identified, featuring unique sensors and regulators, such as the ZBP1-, AIM2-, RIPK1-, and NLRP12-PANoptosomes (10).

Given the crosstalk of apoptosis, pyroptosis and necroptosis in IEC, the researches has demonstrated the important regulator of PANoptosis in the pathogen-induced intestinal inflammation (Figure 2). For example, *S. Typhimurium* effector SopF regulated PANoptosis in IEC to attenuate intestinal inflammation. Specifically, SopF inactivated caspase-8 through the PDK1-RSK signaling, thereby inhibiting apoptosis and pyroptosis of IEC with the promotion of necroptosis. Thus, SopF restricted the dislodging of IECs to promote bacterial dissemination, which exacerbates systemic infection (60). In addition, ventilator-induced lung injury (VILI) substantially promoted the expression of caspase-3, N-GSDMD and p-RIPK3 in the gut due to systemic cytokines, suggesting that PANoptosis involved in VILI-induced gut injury and inflammation in the mice (61).

Recently, PANoptosis has been implicated in the onset and progress of IBD. Based on multiple transcriptome profiles of intestinal mucosal biopsies from the GEO database, bioinformatics analysis identified that four pivotal PANoptosisrelated gene (ZBP1, AIM2, CASP1/8) were significantly activated in UC patients, which regulated specific immune cells and interacted with key signaling pathways contributing to the pathogenesis of UC. These findings were validated in the DSS-induced mouse colitis model (62-64). Another comprehensive study combining bioinformatics, machine learning, and experimentation confirmed that PANoptosis played an undeniable role in CD by regulating the immune system and interacting with CD-related genes (65). The abnormal activation of ZBP1 caused embryonic lethality and intestinal cell death. In mouse models, the knockdown of key sensor molecules of PANoptosis has been shown to rescue the death fate of innate immune-induced epithelial cells (66). Researches indicated the crucial role of IFN- γ in inducing the intestinal epithelial barriers (67). The result obtained from human



intestinal organoid (enteorid) model has shown that PANoptosis is the major mechanism of IFN- γ -induced IEC damage. Furthermore, bulk and single-cell RNA sequencing (RNA-seq) found that PCDassociated gene expression was upregulated in enterocytes and goblet cells, but not in intstinal stem cells and Paneth cells (68). This finding demonstrates IFN- γ -induced intestinal epithelial cell type-specific PANoptosis. Mechanistically, NLRC5 could function as an innate immune sensor in inflammatory conditions and interact with NLRP12 to form a PANoptosome in response to NAD⁺ depletion. Thus, deletion of NLRC5 protect mice from colitis (69). However, this study did not illuminate whether NLRC5mediated PANoptosome formation bears intestinal epithelial cell type specificity.

IFN regulatory factor 1 (IRF1) is a transcription factor of the PANoptosome sensors ZBP1 and NLRP3, and knocking out IRF1 will reduce the expression of PANoptosome core molecules such as NLRP3, CSAP1/3/8, and MLKL in the innate immune response (70, 71). In a UC mouse model, the knockdown of IRF1 also significantly inhibited the expression of colonic apoptosis, pyroptosis, and necroptosis executioner proteins CASP3/7, GSDMD, and MLKL, thus inhibiting PANoptosis (72). Colitisassociated cancer (CAC) is the most serious complication of inflammatory bowel disease, which is driven by long-term inflammatory damage. In the case of CAC, loss of IRF1 suppressed PANoptosis of colon, thereby increasing the susceptibility of Irf1^{-/-} mice to CRC (72). Hence, IRF1 functions as a key upstream mediator of PANoptosis, which could potentially be a therapeutic target for IBD. More in-deep and systematic investigation is warranted to uncover the substantial insights into the essential role of IRF1 in the PANoptosis process of IEC, which is

beneficial for a momentously advanced understanding of the etiology and pathogenesis of IBD.

4.2 Potential nature compounds targeting IEC PANoptosis in IBD

It is widely acknowledged that in pathological contexts, three distinct modalities of cell demise can coexist, exhibiting overlapping mechanisms and functioning as complementary death strategies. For instance, the inhibition of caspase-8 can effectively mitigate the process of apoptosis; however, this intervention may precipitate alternative forms of cell death, such as necroptosis or pyroptosis. Notably, PANapoptosis encompasses all three types of cell death, and thus, targeting PANapoptosis presents a strategic approach to concurrently inhibit these three distinct modes of cell demise.

It's well-established that natural products stemmed from multifarious medicinal plants, vegetables and fruits orchestrate different cell death modalities for IBD treatment with lower costs, flexible dosage adjustments, fewer side effects and long-term application (73, 74). However, no reports delineate natural products regulating PANoptosis of IEC for IBD treatment. Nevertheless, numerous natural products are currently being investigated as PCD regulators for IBD therapy. Natural compounds that modulate both apoptosis and necroptosis or apoptosis and pyroptosis in IEC are listed in Table 1, setting a precursor for research into PANoptosis of IEC in IBD.

HuanglianGanjiang Tang (HGT) is a renowned prescription of traditional Chinese medicine (TCM). HGT obstructed necroptosis in IEC by activating vitamin D receptor (VDR) signaling pathway,

Natural compounds	Cell death	In Vivo/Vitro	Cell lines/Animals	Mechanisms	References
HuanglianGanjiang Tang (HGT) and the compound berberine	Necroptosis	In Vitro	Mice with DSS-induced colitis	Activating vitamin D receptor (VDR) signaling pathway	(75)
berberine	Apoptosis	In Vivo and In Vitro	Caco-2 Cells/ Mice with DSS- induced colitis	Lowering JNK phosphorylation	(76, 77)
	Pyroptosis	In Vivo and In Vitro	Caco-2 Cells/ Mice with DSS- induced colitis	Activating the Wnt/β-catenin pathway via modulating the miR-103a-3p/BRD4 axis	(78)
L. edodes polysaccharides	Necroptosis	In Vivo and In Vitro	Caco-2 Cells/ Mice with DSS- induced colitis	Inhibiting pMLKL- mediated necroptosis	(79)
	Pyroptosis	In Vitro	Human umbilical vein endothelial cells	Regulating the LncRNA MALAT1/miR-199b/mTOR axis and the NLRP3/Caspase-1/ GSDMD pathway	(80)
Traditional herbal formula Wu- Mei-Wan (WMW) and the compound ginsenoside Rb1	Necroptosis	In Vivo	Mice with TNBS-induced colitis	Promoting RIPK3 O- GlcNAcylation and suppressing the binding of RIPK3 and MLKL	(81)
Ginsenoside Rb1	Apoptosis	In Vivo and In Vitro	IEC-6 Cells/ Mice with DSS- and TNBS-induced colitis	Activating Hrd1 signaling pathway	(82)
	Pyroptosis	In Vitro	Non-IEC (astrocytes, hepatocytes and renal cells)	Activating mitophagy	(83-85)
Cucurbitacin E	PANoptosis	In Vitro	Non-IEC	Regulating ZBP1	(86)

TABLE 1 Compounds that induce cell.

thereby attenuating DSS-induced colitis. Furthermore, molecular docking analysis has successfully proved the binding affinity of the five compounds to VDR, including berberine, phellodendrine, 6-Gingerol, ferulic acid and citric acid (75). Previous studies uncovered that berberine could evidently lessen cytokine-induced Caco-2 apoptosis *in vitro* by lowering JNK phosphorylation, thus in turn promoting the recovery of colon epithelium in DSS-treated mice (76, 77). Recently, a research found that berberine weakened colitis-induced pyroptosis and intestinal mucosal barrier defects by activating the Wnt/ β -catenin pathway via modulating the miR-103a-3p/BRD4 axis (78).

The natural compound polysaccharides from the edible mushrooms *Lentinus edodes* showed therapeutic properties on DSS-induced colitis. The carbohydrate-rich component of *L. edodes* polysaccharides suppressed TNF-induced cell death of Caco-2 cells in a dose-dependent manner by inhibiting pMLKLmediated necroptotic cell death, thus counteracting DSS-induced colitis in mice (79). This study also revealed that L. edodes polysaccharides prevented apoptotic cell death in Caco-2 cells (79). The effect of *L. edodes* polysaccharides on pyroptosis is reported in non-IEC. In human umbilical vein endothelial cells, *L. edodes* polysaccharides dampened advanced glycation end products (AGEs)-induced pyroptosis via regulating the LncRNA MALAT1/miR-199b/mTOR axis and the NLRP3/Caspase-1/ GSDMD pathway (80).

Traditional herbal formula Wu-Mei-Wan (WMW) could augment colonic O-GlcNAc transferase (OGT) activity and inhibit O-GlcNAcase (OGA) activity, which may be regulated by the compounds hesperidin, coptisine and ginsenoside Rb1 found in WMW. As a result, WMW could prevent necroptosis through promoting RIPK3 O-GlcNAcylation and suppressing the binding of RIPK3 and MLKL, ultimately alleviating TNBS-induced colitis in mice (81). A previous study demonstrated that ginsenoside Rb1 abated LPS-induced apoptosis via activating Hrd1 signaling pathway in intestinal cell line IEC-6, thus alleviating colitis symptoms in DSS- and TNBS-treated mice (82). Additionally, ginsenoside Rb1 diminished pyroptosis by activating mitophagy in non-IEC, such as astrocytes, hepatocytes and renal cells (83–85). Importantly, forthcoming research endeavors about the effect of ginsenoside Rb1 on the IEC and colitis are necessary.

Cucurbitacin E (CurE), a natural product extracted from plants in the *Cucurbitaceae* family. In the adrenocortical carcinoma cells, is a CDK1 inhibitor. CDK1 regulated the PANoptosis of adrenocortical carcinoma cells through binding with the PANoptosome in a ZBP1 –dependent way (86). Machine learning and integrated bioinformatics identified possible hub genes (AURKB, CDK1, and CCNA2) between bladder cancer and inflammatory bowel disease (87). Further investigation is warranted to confirm whether cucurbitacin E regulates PANoptosis in a ZBP1–dependent way in the context of IBD specifically.

In a word, berberine, *L. edodes* polysaccharides, ginsenoside Rb1 and cucurbitacin E are potential natural compounds that regulate PANoptosis of IEC for the treatment of IBD. These evidence pave the way for future pharmacological research.

5 Conclusion and discussion

Over the past decade, a wealth of evidence has established the basic knowledge on apoptosis, necroptosis and pyroptosis and their

roles in the pathogenesis of IBD. This review followed with interest in the current understanding of the crosstalk between these cell deaths modalities in IEC, particularly in the context of inflammatory bowel disease. However, IEC constitute a heterogeneous population along the gut, embodying absorptive cells, goblet cells, enteroendocrine cells, Paneth cells, M cells, cup cells, and Tuft cells. The significance of location-specific and cell type-specific cell death along the length of the intestine has been highlighted by various transgenic mouse models. Further investigation is needful to unravel the cell death and their crosstalk at single-cell resolution in different IEC types from the intestine, which will potentially illuminate the underlying nature of IBD.

Within the landscape about the crosstalk between apoptosis, necroptosis and pyroptosis in IEC, this review further provided an overview about the IEC PANoptosis in the context of IBD. However, the body of literatures addressing this topic is scant. The study of PANoptosis in IBD remains limited to in preliminary experimental phases. As such, there is an imperative need to probe more intricately into the underlying mechanisms governing PANoptosis and the upstream modulators in IEC through both foundational research and clinical trials. This endeavor will undoubtedly foster the emergence of innovative and more efficacious treatment strategies for IBD.

Given the well-established role of natural products in the prevention and treatment of IBD, coupled with their minimal adverse effects, this review also highlights potential nature compounds targeting IEC PANoptosis for IBD treatment based on the limited literatures. This merits further attention and contemplation. We hope to provide a solid groundwork for researchers in this field to explore the potential drugs for IBD treatment in the foreseeable future.

Author contributions

CZ: Conceptualization, Funding acquisition, Writing – original draft. SL: Investigation, Visualization, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Huai'an Natural Science Research Program (grant numbers HAB202372).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. El Hadad J, Schreiner P, Vavricka SR, Greuter T. The genetics of inflammatory bowel disease. *Mol Diagnosis Ther.* (2023) 28:27–35. doi: 10.1007/s40291-023-00678-7

2. Liu T-C, Stappenbeck TS. Genetics and pathogenesis of inflammatory bowel disease. *Annu Rev Pathology: Mech Dis.* (2016) 11:127–48. doi: 10.1146/annurev-pathol-012615-044152

3. Wang S, Dong Z, Wan X. Global, regional, and national burden of inflammatory bowel disease and its associated anemia, 1990 to 2019 and predictions to 2050: an analysis of the global burden of disease study 2019. *Autoimmun Rev.* (2024) 23:103498. doi: 10.1016/j.autrev.2023.103498

4. Ramos GP, Papadakis KA. Mechanisms of disease: inflammatory bowel diseases. *Mayo Clinic Proc.* (2019) 94:155–65. doi: 10.1016/j.mayocp.2018.09.013

5. Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? *Gut.* (2007) 56:453–5. doi: 10.1136/ gut.2005.088732

6. Marotti V, Xu Y, Bohns Michalowski C, Zhang W, Domingues I, Ameraoui H, et al. A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment. *Bioactive Materials*. (2024) 32:206–21. doi: 10.1016/j.bioactmat.2023.09.014

7. Patankar JV, Becker C. Cell death in the gut epithelium and implications for chronic inflammation. *Nat Rev Gastroenterol Hepatol.* (2020) 17:543–56. doi: 10.1038/ s41575-020-0326-4

 Blander JM. Death in the intestinal epithelium—Basic biology and implications for inflammatory bowel disease. FEBS J. (2016) 283:2720–30. doi: 10.1111/febs.13771

9. Newton K, Strasser A, Kayagaki N, Dixit VM. Cell death. *Cell*. (2024) 187:235–56. doi: 10.1016/j.cell.2023.11.044

10. Sun X, Yang Y, Meng X, Li J, Liu X, Liu H. Panoptosis: mechanisms, biology, and role in disease. *Immunol Rev.* (2023) 321:246–62. doi: 10.1111/imr.13279

11. Qi Z, Zhu L, Wang K, Wang N. Panoptosis: emerging mechanisms and disease implications. *Life Sci.* (2023) 333:122158. doi: 10.1016/j.lfs.2023.122158

12. Kerr JF WA, Currie AR. Apoptosis a basic biological phenomenon with wideranging implications in tissue kinetics. *Br J Cancer*. (1972) 26:239–57. doi: 10.1038/ bjc.1972.33

13. Zou H HW, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to C. Elegans ced-4, participates in cytochrome C-dependent activation of caspase-3. *Cell.* (1997) 90:405–13. doi: 10.1016/s0092-8674(00)80501-2

14. Li P ND, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X. Cytochrome C and datp-dependent formation of apaf-1caspase-9 complex initiates an apoptotic protease cascade. *Cell.* (1997) 91:479–89. doi: 10.1016/s0092-8674(00) 80434-1

15. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. *Nat Chem Biol.* (2005) 1:112–9. doi: 10.1038/nchembio711

16. Chen W, Zhou Z, Li L, Zhong C-Q, Zheng X, Wu X, et al. Diverse sequence determinants control human and mouse receptor interacting protein 3 (Rip3) and mixed lineage kinase domain-like (Mlkl) interaction in necroptotic signaling. *J Biol Chem.* (2013) 288:16247–61. doi: 10.1074/jbc.M112.435545

17. Samson AL, Zhang Y, Geoghegan ND, Gavin XJ, Davies KA, Mlodzianoski MJ, et al. Mlkl trafficking and accumulation at the plasma membrane control the kinetics and threshold for necroptosis. *Nat Commun.* (2020) 11:3151. doi: 10.1038/s41467-020-16887-1

18. Friedlander AM. Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. *J Biol Chem*. (1986) 261:7123–6. doi: 10.1016/s0021-9258(17) 38364-3

19. Dostert C, Meylan E, Tschopp J. Intracellular pattern-recognition receptors☆. Advanced Drug Delivery Rev. (2008) 60:830–40. doi: 10.1016/j.addr.2007.12.003

20. He W-t, Wan H, Hu L, Chen P, Wang X, Huang Z, et al. Gasdermin D is an executor of pyroptosis and required for interleukin-1 β Secretion. *Cell Res.* (2015) 25:1285–98. doi: 10.1038/cr.2015.139

21. Kayagaki N, Stowe IB, Lee BL, O'Rourke K, Anderson K, Warming S, et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. *Nature*. (2015) 526:666–71. doi: 10.1038/nature15541

22. Ghait M, Duduskar SN, Rooney M, Häfner N, Reng L, Göhrig B, et al. The noncanonical inflammasome activators caspase-4 and caspase-5 are differentially regulated during immunosuppression-associated organ damage. *Front Immunol.* (2023) 14:1239474. doi: 10.3389/fimmu.2023.1239474

23. Gao W, Li Y, Liu X, Wang S, Mei P, Chen Z, et al. Trim21 regulates pyroptotic cell death by promoting gasdermin D oligomerization. *Cell Death Differentiation*. (2021) 29:439–50. doi: 10.1038/s41418-021-00867-z

24. Wang Y, Gao W, Shi X, Ding J, Liu W, He H, et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. *Nature*. (2017) 547:99–103. doi: 10.1038/nature22393

25. Zhang J-y, Zhou B, Sun R-y, Ai Y-l, Cheng K, F-n Li, et al. The metabolite A-kg induces gsdmc-dependent pyroptosis through death receptor 6-activated caspase-8. *Cell Res.* (2021) 31:980–97. doi: 10.1038/s41422-021-00506-9

26. Zhou Z HH, Wang K, Shi X, Wang Y, Su Y, Wang Y, et al. Granzyme a from cytotoxic lymphocytes cleaves gsdmb to trigger pyroptosis in target cells. *Science*. (2020) 368:eaaz7548. doi: 10.1126/science.aaz7548

27. Zhang Z, Zhang Y, Xia S, Kong Q, Li S, Liu X, et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. *Nature*. (2020) 579:415–20. doi: 10.1038/s41586-020-2071-9

28. Wang L, Du F, Wang X. Tnf-A Induces two distinct caspase-8 activation pathways. Cell. (2008) 133:693-703. doi: 10.1016/j.cell.2008.03.036

29. Feng S, Yang Y, Mei Y, Ma L, D-e Z, Hoti N, et al. Cleavage of rip3 inactivates its caspase-independent apoptosis pathway by removal of kinase domain. *Cell Signalling*. (2007) 19:2056–67. doi: 10.1016/j.cellsig.2007.05.016

30. Newton K, Wickliffe KE, Dugger DL, Maltzman A, Roose-Girma M, Dohse M, et al. Cleavage of ripk1 by caspase-8 is crucial for limiting apoptosis and necroptosis. *Nature*. (2019) 574:428–31. doi: 10.1038/s41586-019-1548-x

31. Schwarzer R, Jiao H, Wachsmuth L, Tresch A, Pasparakis M. Fadd and caspase-8 regulate gut homeostasis and inflammation by controlling mlkl- and gsdmd-mediated death of intestinal epithelial cells. *Immunity*. (2020) 52:978–93.e6. doi: 10.1016/j.immuni.2020.04.002

32. Gurung P, Anand PK, Malireddi RKS, Vande Walle L, Van Opdenbosch N, Dillon CP, et al. Fadd and caspase-8 mediate priming and activation of the canonical and noncanonical nlrp3 inflammasomes. *J Immunol.* (2014) 192:1835–46. doi: 10.4049/jimmunol.1302839

33. Sarhan J, Liu BC, Muendlein HI, Li P, Nilson R, Tang AY, et al. Caspase-8 induces cleavage of gasdermin D to elicit pyroptosis during yersinia infection. *Proc Natl Acad Sci.* (2018) 115:122158. doi: 10.1073/pnas.1809548115

34. Fukata M, Chen A, Klepper A, Krishnareddy S, Vamadevan AS, Thomas LS, et al. Cox-2 is regulated by toll-like receptor-4 (Tlr4) signaling: role in proliferation and apoptosis in the intestine. *Gastroenterology*. (2006) 131:862–77. doi: 10.1053/j.gastro.2006.06.017

35. Van Opdenbosch N, Van Gorp H, Verdonckt M, Saavedra PHV, de Vasconcelos NM, Gonçalves A, et al. Caspase-1 engagement and tlr-induced C-flip expression suppress asc/caspase-8-dependent apoptosis by inflammasome sensors nlrp1b and nlrc4. *Cell Rep.* (2017) 21:3427–44. doi: 10.1016/j.celrep.2017.11.088

36. Welz P-S, Wullaert A, Vlantis K, Kondylis V, Fernández-Majada V, Ermolaeva M, et al. Fadd prevents rip3-mediated epithelial cell necrosis and chronic intestinal inflammation. *Nature*. (2011) 477:330–4. doi: 10.1038/nature10273

37. Günther C, Buchen B, He G-W, Hornef M, Torow N, Neumann H, et al. Caspase-8 controls the gut response to microbial challenges by tnf-A-dependent and independent pathways. *Gut.* (2015) 64:601–10. doi: 10.1136/gutjnl-2014-307226

38. Günther C, Martini E, Wittkopf N, Amann K, Weigmann B, Neumann H, et al. Caspase-8 regulates tnf-A-induced epithelial necroptosis and terminal ileitis. *Nature*. (2011) 477:335–9. doi: 10.1038/nature10400

39. Hefele M, Stolzer I, Ruder B, He G-W, Mahapatro M, Wirtz S, et al. Intestinal epithelial caspase-8 signaling is essential to prevent necroptosis during salmonella typhimurium induced enteritis. *Mucosal Immunol.* (2018) 11:1191–202. doi: 10.1038/ s41385-018-0011-x

40. Dannappel M, Vlantis K, Kumari S, Polykratis A, Kim C, Wachsmuth L, et al. Ripk1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis. *Nature*. (2014) 513:90-4. doi: 10.1038/nature13608

41. Lehle AS, Farin HF, Marquardt B, Michels BE, Magg T, Li Y, et al. Intestinal inflammation and dysregulated immunity in patients with inherited caspase-8 deficiency. *Gastroenterology*. (2019) 156:275-8. doi: 10.1053/ j.gastro.2018.09.041 42. Kiesslich R, Goetz M, Angus EM, Hu Q, Guan Y, Potten C, et al. Identification of epithelial gaps in human small and large intestine by confocal endomicroscopy. *Gastroenterology*. (2007) 133:1769–78. doi: 10.1053/j.gastro.2007.09.011

43. Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. *Nat Rev Mol Cell Biol.* (2010) 11:700–14. doi: 10.1038/nrm2970

44. Li M BA. Induction of necrotic-like cell death by tumor necrosis factor alpha and caspase inhibitors novel mechanism for killing virus-infected cells. *J Virol.* (2000) 74:7470–7. doi: 10.1128/jvi.74.16.7470-7477.2000

45. Ashida H, Sasakawa C, Suzuki T. A unique bacterial tactic to circumvent the cell death crosstalk induced by blockade of caspase-8. *EMBO J.* (2020) 39:e104469. doi: 10.15252/embj.2020104469

46. Ruder B, Murtadak V, Stürzl M, Wirtz S, Distler U, Tenzer S, et al. Chronic intestinal inflammation in mice expressing viral flip in epithelial cells. *Mucosal Immunol.* (2018) 11:1621–9. doi: 10.1038/s41385-018-0068-6

47. Lamkanfi M, Kanneganti T-D, Van Damme P, Vanden Berghe T, Vanoverberghe I, Vandekerckhove J, et al. Targeted peptidecentric proteomics reveals caspase-7 as a substrate of the caspase-1 inflammasomes. *Mol Cell Proteomics*. (2008) 7:2350-63. doi: 10.1074/mcp.M800132-MCP200

48. Tsuchiya K, Nakajima S, Hosojima S, Thi Nguyen D, Hattori T, Manh Le T, et al. Caspase-1 initiates apoptosis in the absence of gasdermin D. *Nat Commun.* (2019) 10:2091. doi: 10.1038/s41467-019-09753-2

49. Rogers C, Erkes DA, Nardone A, Aplin AE, Fernandes-Alnemri T, Alnemri ES. Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation. *Nat Commun.* (2019) 10:1689. doi: 10.1038/ s41467-019-09397-2

50. Rana N, Privitera G, Kondolf HC, Bulek K, Lechuga S, De Salvo C, et al. Gsdmb is increased in ibd and regulates epithelial restitution/repair independent of pyroptosis. *Cell.* (2022) 185:283–98.e17. doi: 10.1016/j.cell.2021.12.024

51. Bulek K, Zhao J, Liao Y, Rana N, Corridoni D, Antanaviciute A, et al. Epithelialderived gasdermin D mediates nonlytic il-1 β Release during experimental colitis. *J Clin Invest.* (2020) 130:4218–34. doi: 10.1172/jci138103

52. Tan G, Huang C, Chen J, Chen B, Zhi F. Gasdermin-E-mediated pyroptosis participates in the pathogenesis of crohn's disease by promoting intestinal inflammation. *Cell Rep.* (2021) 35:109265. doi: 10.1016/j.celrep.2021.109265

53. Newton K, Wickliffe KE, Maltzman A, Dugger DL, Reja R, Zhang Y, et al. Activity of caspase-8 determines plasticity between cell death pathways. *Nature*. (2019) 575:679–82. doi: 10.1038/s41586-019-1752-8

54. Fritsch M, Günther SD, Schwarzer R, Albert M-C, Schorn F, Werthenbach JP, et al. Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis. *Nature*. (2019) 575:683–7. doi: 10.1038/s41586-019-1770-6

55. Lawlor KE, Khan N, Mildenhall A, Gerlic M, Croker BA, D'Cruz AA, et al. Ripk3 promotes cell death and nlrp3 inflammasome activation in the absence of mlkl. *Nat Commun.* (2015) 6:6282. doi: 10.1038/ncomms7282

56. Kang S, Fernandes-Alnemri T, Rogers C, Mayes L, Wang Y, Dillon C, et al. Caspase-8 scaffolding function and mlkl regulate nlrp3 inflammasome activation downstream of tlr3. *Nat Commun.* (2015) 6:7515. doi: 10.1038/ncomms8515

57. Gutierrez KD, Davis MA, Daniels BP, Olsen TM, Ralli-Jain P, Tait SWG, et al. Mlkl activation triggers nlrp3-mediated processing and release of il-1 β Independently of gasdermin-D. *J Immunol.* (2017) 198:2156–64. doi: 10.4049/jimmunol.1601757

58. Lei X CY, Lien E, Fitzgerald KA. Mlkl-driven inflammasome activation and caspase-8 mediate inflammatory cell death in influenza a virus infection. *mBio*. (2023) 14:e0011023. doi: 10.1128/mbio.00110-23

59. Malireddi RKS, Kesavardhana S, Kanneganti T-D. Zbp1 and tak1: master regulators of nlrp3 inflammasome/pyroptosis, apoptosis, and necroptosis (Panoptosis). *Front Cell Infection Microbiol.* (2019) 9:406. doi: 10.3389/fcimb.2019.00406

60. Yuan H, Zhou L, Chen Y, You J, Hu H, Li Y, et al. Salmonella effector sopf regulates panoptosis of intestinal epithelial cells to aggravate systemic infection. *Gut Microbes.* (2023) 15:2180315. doi: 10.1080/19490976.2023.2180315

61. Ding N, Xiao H, Zhen L, Li H, Zhang Z, Ge J, et al. Systemic cytokines inhibition with imp7 sirna nanoparticle ameliorates gut injury in a mouse model of ventilatorinduced lung injury. *Biomedicine Pharmacotherapy*. (2023) 165:115237. doi: 10.1016/ j.biopha.2023.115237

62. Wang J-M, Yang J, Xia W-Y, Wang Y-M, Zhu Y-B, Huang Q, et al. Comprehensive analysis of panoptosis-related gene signature of ulcerative colitis. *Int J Mol Sci.* (2023) 25:348. doi: 10.3390/ijms25010348

63. Ji Y, Li P, Ning T, Yang D, Shi H, Dong X, et al. Panoptosis-related genes: molecular insights into immune dysregulation in ulcerative colitis. *J Gastroenterol Hepatol.* (2024). doi: 10.1111/jgh.16804

64. Lu J, Li F, Ye M. Panoptosis and autophagy-related molecular signature and immune landscape in ulcerative colitis: integrated analysis and experimental validation. *J Inflammation Res.* (2024) 17:3225–45. doi: 10.2147/jir.S455862

65. Yang Y, Hounye AH, Chen Y, Liu Z, Shi G, Xiao Y. Characterization of panoptosis-related genes in crohn's disease by integrated bioinformatics, machine learning and experiments. *Sci Rep.* (2024) 14:11731. doi: 10.1038/s41598-024-62259-w

66. Hubbard NW, Ames JM, Maurano M, Chu LH, Somfleth KY, Gokhale NS, et al. Adar1 mutation causes zbp1-dependent immunopathology. *Nature*. (2022) 607:769–75. doi: 10.1038/s41586-022-04896-7

67. Woznicki JA, Saini N, Flood P, Rajaram S, Lee CM, Stamou P, et al. Tnf-A Synergises with ifn- Γ to induce caspase-8-jak1/2-stat1-dependent death of intestinal epithelial cells. *Cell Death Dis.* (2021) 12:864. doi: 10.1038/s41419-021-04151-3

68. Hong SN, Chansu L, Minjee K, Yujin L, Songee B, Eun K, et al. P087 ifn-Γinduced intestinal epithelial cell type-specific cytotoxic responses of human enteroids panoptosis and the protective role of selective jak1 inhibitors. *J Crohn's Colitis*. (2024) 18:i363. doi: 10.1093/ecco-jcc/jjad212.0217

69. Sundaram B, Pandian N, Kim HJ, Abdelaal HM, Mall R, Indari O, et al. Nlrc5 senses nad+ Depletion, forming a panoptosome and driving panoptosis and inflammation. *Cell.* (2024) 187:4061–77.e17. doi: 10.1016/j.cell.2024.05.034

70. Sharma BR, Karki R, Rajesh Y, Kanneganti T-D. Immune regulator irfl contributes to zbp1-, aim2-, ripk1-, and nlrp12-panoptosome activation and inflammatory cell death (Panoptosis). *J Biol Chem.* (2023) 299:105141. doi: 10.1016/j.jbc.2023.105141

71. Kuriakose T, Zheng M, Neale G, Kanneganti T-D. Irfl is a transcriptional regulator of zbp1 promoting nlrp3 inflammasome activation and cell death during influenza virus infection. *J Immunol.* (2018) 200:1489–95. doi: 10.4049/jimmunol.1701538

72. Karki R, Sharma BR, Lee E, Banoth B, Malireddi RKS, Samir P, et al. Interferon regulatory factor 1 regulates panoptosis to prevent colorectal cancer. *JCI Insight*. (2020) 5:e136720. doi: 10.1172/jci.insight.136720

73. Chen B DX, Zhang JL, Sun X, Zhou L, Zhao K, Deng H, et al. Natural compounds target programmed cell death (Pcd) signaling mechanism to treat ulcerative colitis a review. *Front Pharmacol.* (2024) 15:1333657. doi: 10.3389/fphar.2024.1333657

74. Liu C, Zeng Y, Wen Y, Huang X, Liu Y. Natural products modulate cell apoptosis: A promising way for the treatment of ulcerative colitis. *Front Pharmacol.* (2022) 13:806148. doi: 10.3389/fphar.2022.806148

75. Xiong X, Cheng Z, Zhou Y, Wu F, Xie L, Lawless L, et al. Huanglianganjiang tang alleviates dss-induced colitis in mice by inhibiting necroptosis through vitamin D receptor. *J Ethnopharmacology.* (2022) 298:115655. doi: 10.1016/j.jep.2022.115655

76. Hao X, Yao A, Gong J, Zhu W, Li N, Li J. Berberine ameliorates pro-inflammatory cytokine-induced endoplasmic reticulum stress in human intestinal epithelial cells *in vitro*. *Inflammation*. (2011) 35:841–9. doi: 10.1007/s10753-011-9385-6

77. Yan F, Wang L, Shi Y, Cao H, Liu L, Washington MK, et al. Berberine promotes recovery of colitis and inhibits inflammatory responses in colonic macrophages and epithelial cells in dss-treated mice. *Am J Physiology-Gastrointestinal Liver Physiol.* (2012) 302:G504–G14. doi: 10.1152/ajpgi.00312.2011

78. Zhao X, Cui D, Yuan W, Chen C, Liu Q. Berberine represses wnt/B-catenin pathway activation via modulating the microrna-103a-3p/bromodomain-containing protein 4 axis, thereby refraining pyroptosis and reducing the intestinal mucosal barrier defect induced via colitis. *Bioengineered.* (2022) 13:7392–409. doi: 10.1080/21655979.2022.2047405

79. Alagbaoso CA MM. Polysaccharides from shiitake culinary-medicinal mushroom lentinus edodes (Agaricomycetes) suppress pmlkl-mediated necroptotic cell death and colitis in mice. *Int J Med Mushrooms*. (2021) 23:13–26. doi: 10.1615/ IntJMedMushrooms.2021038850

80. Liu D, Mei X, Mao Y, Li Y, Wang L, Cao X. Lentinus edodes mycelium polysaccharide inhibits ages-induced huvecs pyroptosis by regulating lncrna malat1/ mir-199b/mtor axis and nlrp3/caspase-1/gsdmd pathway. *Int J Biol Macromolecules*. (2024) 267:131387. doi: 10.1016/j.ijbiomac.2024.131387

81. Wu F, Shao Q, Cheng Z, Xiong X, Fang K, Zhao Y, et al. Traditional herbal formula wu-mei-wan alleviates tnbs-induced colitis in mice by inhibiting necroptosis through increasing ripk3 O-glcnacylation. *Chin Med.* (2021) 16:78. doi: 10.1186/s13020-021-00493-4

82. Dong J-y, Xia K-j, Liang W, Liu L-l, Yang F, Fang X-s, et al. Ginsenoside rb1 alleviates colitis in mice via activation of endoplasmic reticulum-resident E3 ubiquitin ligase hrd1 signaling pathway. *Acta Pharmacologica Sin*. (2020) 42:1461–71. doi: 10.1038/s41401-020-00561-9

83. Li Y, Li J, Yang L, Ren F, Dong K, Zhao Z, et al. Ginsenoside rb1 protects hippocampal neurons in depressed rats based on mitophagy-regulated astrocytic pyroptosis. *Phytomedicine*. (2023) 121:155083. doi: 10.1016/j.phymed.2023.155083

84. Zhang Q, Hu J, Mao A, Liu M, Guan S, Lu J. Ginsenoside rb1 alleviated concanavalin a-induced hepatocyte pyroptosis by activating mitophagy. *Food Funct.* (2023) 14:3793–803. doi: 10.1039/d2fo03130b

85. Zhang R, Guan S, Meng Z, Zhang D, Lu J. Ginsenoside rb1 alleviates 3-mcpdinduced renal cell pyroptosis by activating mitophagy. *Food Chem Toxicol.* (2024) 186:114522. doi: 10.1016/j.fct.2024.114522

86. Ren L, Yang Y, Li W, Zheng X, Liu J, Li S, et al. Cdk1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial-mesenchymal transition, G2/M phase transition, and panoptosis. *J Trans Med.* (2022) 20:444. doi: 10.1186/s12967-022-03641-y

87. Liu J, Wu P, Lai S, Wang J, Wang J, Zhang Y. Identifying possible hub genes and biological mechanisms shared between bladder cancer and inflammatory bowel disease using machine learning and integrated bioinformatics. *J Cancer Res Clin Oncol.* (2023) 149:16885–904. doi: 10.1007/s00432-023-05266-0